{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 11,
  "pageCount": 40,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "context",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a three-part process flow to explain the biological mechanism of ROS1-driven disease and resistance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/11",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Three-stage process: ROS1 WT, Oncogenic ROS1 Rearrangements, Secondary Resistance Mutations",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f64c75f2-f0f2-4ae5-bbd2-bbcbcde4d266",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Abbreviations: Non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor (IMT), salivary gland carcinoma (SGC), papillary thyroid carcinoma (PTC), anaplastic large cell lymphoma (ALCL), serous ovarian carcinoma (SOC), and inflammatory hepatocelluar adenoma (IHCA)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02378d16-13d8-48bf-97ca-0609db6b817f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "list",
      "text": "ROS1-deficient mice are viable... In humans, highest expression in epididymis and lung",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fd3e23d-1eb7-4207-ba68-d0b0349404d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.66,
        "y": 0.62
      },
      "kind": "list",
      "text": "Kinase domain mutations in ROS1 confer resistance... Solvent front mutation... Additional mutations such as S1986Y/F and gatekeeper mutation L2026M",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "439dae30-0cb5-4f92-8f5d-cea441a066dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.35,
        "y": 0.62
      },
      "kind": "list",
      "text": "Rearrangements may result in transmembrane or intracellular ROS1 fusions... ROS1 fusions have been identified across multiple solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a37dd605-9c06-461c-879f-7c8fec2c564b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Sources: Drilon et. al. Nat Rev Clin Oncol 2021; Lin and Shaw 2017 JTO; The Human Protein Atlas; Structure image from Lin and Shaw 2017 JTO",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4000d1dd-eb26-4ecb-82fc-051d6d881027",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "title",
      "text": "Genomic alterations lead to tumorigenesis and confer treatment resistance",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58e7f4ff-2309-445b-b1fc-650dc9c330b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.07,
        "y": 0.11
      },
      "kind": "title",
      "text": "ROS1 Receptor Tyrosine Kinase",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6a1973c-cd79-4e01-a326-ee448f19d325",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "ccb2ac04-6454-4c22-8e47-d847a118315b",
      "evidence": "The slide features a three-stage process diagram.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "b57f7697-c53d-4d09-968f-9aaf40fc87f3",
      "evidence": "The slide maps the progression from wild-type function to oncogenic rearrangement to resistance mutations.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}